AIP
NWBO

Almanack Investment Partners’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History

Almanack Investment Partners’s Portfolio NWBO Stock Details NWBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-22,000
Closed -$14K – 983
2022
Q2 		$14K Hold
22,000
– – ﹤0.01% 456
2022
Q1 		$15K Sell
22,000
-20,000
-48% -$13.6K ﹤0.01% 492
2021
Q4 		$29K Buy
42,000
+19,500
+87% +$13.5K ﹤0.01% 515
2021
Q3 		$29K Hold
22,500
– – ﹤0.01% 507
2021
Q2 		$33K Hold
22,500
– – ﹤0.01% 444
2021
Q1 		$34K Hold
22,500
– – ﹤0.01% 433
2020
Q4 		$34K Buy
+22,500
New +$34K ﹤0.01% 389

Other funds holding NWBO

SL
Sentinus LLC Oak Brook, Illinois $1.11B AUM 17.13% 1-Year Est. Return
AA
Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return
MSAM
Moloney Securities Asset Management Manchester, Missouri $840M AUM 18.11% 1-Year Est. Return
OCG
Opus Capital Group Cincinnati, Ohio $1.03B AUM 20.67% 1-Year Est. Return
WJWM
Williams Jones Wealth Management New York $8.14B AUM 19.32% 1-Year Est. Return
LDB
Lee, Danner & Bass Nashville, Tennessee $1.73B AUM 36.69% 1-Year Est. Return
AA
AlphaMark Advisors Ft. Wright, Kentucky $231M AUM 19.98% 1-Year Est. Return
GWI
Grace & White Inc Ny, New York $632M AUM 34.34% 1-Year Est. Return
GG
Gofen & Glossberg Chicago, Illinois $3.89B AUM 11.97% 1-Year Est. Return
ECM
Estabrook Capital Management New York $685M AUM 26.64% 1-Year Est. Return

Almanack Investment Partners's NWBO Position: Q3 2022 in Review

Almanack Investment Partners sold out of Northwest Biotherapeutics, Inc. Common stock (NWBO) in Q3 2022, closing a stake of 22,000 shares — an estimated $14K sold.

Almanack Investment Partners first reported a position in NWBO in Q4 2020 and held it in 7 quarters. The position peaked at $34K in Q1 2021. 13 funds tracked by Wall St. Rank hold NWBO as of Q3 2022.

  • Almanack Investment Partners reported no remaining Northwest Biotherapeutics, Inc. Common stock position as of Q3 2022 after selling out during the quarter.
  • Almanack Investment Partners sold 22,000 Northwest Biotherapeutics, Inc. Common stock shares in Q3 2022, an estimated $14K.
  • Almanack Investment Partners first reported a position in Northwest Biotherapeutics, Inc. Common stock in Q4 2020 and held it in 7 quarters.
  • Almanack Investment Partners's Northwest Biotherapeutics, Inc. Common stock position peaked at $34K in Q1 2021.
  • 13 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. Common stock as of Q3 2022.

Based on Almanack Investment Partners's 13F filing for Q3 2022, filed 15 Nov 2022.